Kyverna Therapeutics Inc (NASDAQ:KYTX)’s traded shares stood at 0.47 million during the last session, with the company’s beta value hitting 2.18. At the close of trading, the stock’s price was $2.38, to imply an increase of 4.85% or $0.11 in intraday trading. The KYTX share’s 52-week high remains $28.05, putting it -1078.57% down since that peak but still an impressive 5.46% since price per share fell to its 52-week low of $2.25. The company has a valuation of $102.75M, with an average of 0.31 million shares in intraday trading volume over the past 10 days and average of 339.13K shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for Kyverna Therapeutics Inc (KYTX), translating to a mean rating of 1.29. Of 1 analyst(s) looking at the stock, 0 analyst(s) give KYTX a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 0 recommend it as a Buy.
Kyverna Therapeutics Inc (NASDAQ:KYTX) trade information
After registering a 4.85% upside in the last session, Kyverna Therapeutics Inc (KYTX) has traded red over the past five days. The 5-day price performance for the stock is -4.80%, and -16.20% over 30 days. With these gigs, the year-to-date price performance is -36.36%. Short interest in Kyverna Therapeutics Inc (NASDAQ:KYTX) saw shorts transact 3.05 million shares and set a 9.44 days time to cover.
KYTX Dividends
Kyverna Therapeutics Inc has its next earnings report out on 2024-Nov-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Kyverna Therapeutics Inc (NASDAQ:KYTX)’s Major holders
Kyverna Therapeutics Inc insiders hold 1.22% of total outstanding shares, with institutional holders owning 85.12% of the shares at 86.17% float percentage. In total, 85.12% institutions holds shares in the company, led by VIDA VENTURES ADVISORS, LLC. As of 2024-06-30, the company held over 4.52 million shares (or 10.4901% of shares), all amounting to roughly $33.93 million.
The next major institution holding the largest number of shares is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with 3.37 million shares, or about 7.8106% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $25.26 million.
We also have JPMorgan Small Cap Growth Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Kyverna Therapeutics Inc (KYTX) shares. Going by data provided on Dec 31, 2024 , JPMorgan Small Cap Growth Fund holds roughly 1.0 shares. This is just over 2.32% of the total shares, with a market valuation of $2.39 million. Data from the same date shows that the other fund manager holds a little less at 806.42, or 1.87% of the shares, all valued at about 1.92 million.
